Phase II trial of cisplatin and capecitabine in patients with squamous cell carcinoma of the head and neck, and correlative study of angiogenic factors

The combination of cisplatin and capecitabine was evaluated in patients with recurrent or unresectable squamous cell carcinoma of the head and neck (HNSCC), and outcome parameters were correlated with the expression of thymidine phosphorylase (TP), thymidilate synthetase (TS), vascular endothelial growth factor receptor (VEGFR) 1–3, and microvessel density (MVD). Patients with recurrent or unresectable HNSCC were eligible if they had received prior neoadjuvant chemotherapy, concurrent chemoradiotherapy, or no prior systemic therapy. Patients received cisplatin (75 mg m\(^{-2}\) day 1), and capecitabine (2000 mg m\(^{-2}\) day 1–14) every 3 weeks. A total of 41 patients received 194 cycles. In all, 16 complete responses (39%) and 12 partial responses (29%) were documented, for an overall response rate of 68% (95% CI, 53–80%). Grade 3–4 uncomplicated neutropenia was documented in five subjects. Asthenia, anorexia, hand–foot syndrome, and constipation were the most frequent nonhaematologic events. Median progression-free and overall survival were 6.4 and 12.6 months. Cytoplasmic TP expression was more prevalent in patients with a recurrence vs primary disease. Microvessel density count was higher in patients with recurrent vs primary disease. The combination of cisplatin and capecitabine is effective in recurrent or unresectable HNSCC, and shows a manageable toxicity.

British Journal of Cancer (2004) 91, 2005–2011. doi:10.1038/sj.bjc.6602275 www.bjcancer.com
Published online 14 December 2004
© 2004 Cancer Research UK

Keywords: cisplatin; capecitabine; head and neck squamous cell carcinoma

Head and neck squamous cell carcinoma (HNSCC) accounts for most malignancies that arise in the head and neck region (Liggett and Forastiere, 1995). Two-thirds of the patients present with advanced locoregional disease, and despite combined modality approaches with chemotherapy and radiotherapy or surgery, locoregional and distant failure occurs in up to 60 and 25% of the patients, respectively, and the 3-year survival rate remains below 30% (Dimery and Hong, 1993; Jacobs, 1994). The combination of cisplatin and infusional 5-fluorouracil (5FU) is a widely accepted schedule in the locally advanced or recurrent disease setting, with response rates of 60–80 and 30–40%, respectively; in the latter setting, median overall survival is 6 months (Campbell et al., 1987; Forastiere et al., 1992; Jacobs et al., 1992; Clavel et al., 1994).

Capecitabine (Xeloda™) is an oral fluoropyrimidine prodrug that is efficiently absorbed in the gastrointestinal tract and then transformed by a sequence of reactions to 5'-deoxy-5-fluorocytidine (5'DFCR), deoxyluridine (5'DFUR), and finally to 5-fluorouracil (5FU) by thymidine phosphorylase (TP). Thymidine phosphorylase is preferentially expressed in malignant cells and is responsible for the higher intratumoral vs systemic 5FU concentrations found after capecitabine administration (Kono et al., 1983; Takebayashi et al., 1996). Capecitabine results in tissue to plasma 5FU concentration ratios higher than intravenous 5FU (Ishikawa et al., 1998a, b). The synergistic activity found between cisplatin and 5FU prompted the evaluation of the combination of both agents in a phase I, disease-directed study in 21 patients with recurrent HNSCC; the recommended doses were cisplatin 100 mg m\(^{-2}\) on day one of a 21-day cycle, and capecitabine 1000 mg m\(^{-2}\) bid days 1–14 (Pivot et al., 2003).

Thymidine phosphorylase is a relevant target by being both an angiogenesis-promoting factor, and the intracellular activator of 5FU prodrugs. This enzyme is widely expressed in humans cancers (Zimmerman and Seidenberg, 1964), and higher levels of TP expression are associated with increased intratumoral microvessel density (MVD) and an unfavourable prognosis (Okamoto et al., 2001). Nuclear TP (TP-nuc) correlated with MVD, and was inversely related with response and outcome in HNSCC patients treated with 5FU, cisplatin and radiotherapy (Koukourakis et al., 2000). However, the relationship between these and other
angiogenic-related factors, such as the expression of the vascular endothelial growth factor receptors (VEGFR) 1–3, and outcome parameters of HNSCC patients treated with cisplatin and capecitabine, has not been explored. The present study addresses these issues, while evaluating the feasibility and clinical activity of the combination of cisplatin and capecitabine in recurrent or unresectable HNSCC.

PATIENTS AND METHODS

Patient eligibility

Patients were required to have 18 years of age or older with histologically documented HNSCC that was recurrent or unresectable, measurable disease, Karnofsky performance status (KPS) ≥70, life expectancy of 12 weeks or longer, and adequate bone marrow, hepatic and renal function (absolute neutrophil count (ANC) ≥2.0 \times 10^{9}/l, platelet count ≥100 \times 10^{9}/l, haemoglobin level ≥10.0 g dl^{-1}, AST or ALT levels of <1.5 \times the upper limit of normal, alkaline phosphatase level <5 \times the upper limit of normal, normal bilirubin level, and a creatinine clearance ≥50 ml min^{-1}). Patients could have received one prior regimen of chemotherapy as neoadjuvant, adjuvant or concurrent therapy with radiation, as long as it was terminated more than 6 months before disease recurrence. Patients with grade 2 or higher peripheral neuropathy or other serious medical or psychiatric condition were excluded. The scientific review board of our institution granted protocol approval. Patients were required to provide written informed consent prior to enrolment into the study. Within 3 weeks before study entry, a computed tomography (CT) scan of the head and neck was performed. Within 1 week of study entry, all patients had a complete clinical history and physical examination, complete blood counts, serum biochemistry tests (liver and renal function tests, and electrolytes), urinalysis, and electrocardiogram.

Treatment plan

Treatment consisted of cisplatin (75 mg m^{-2} as a 30-min i.v. infusion on day 1), followed by capecitabine (1000 mg m^{-2} orally twice daily, on days 1 – 14), every 21 days. Standard mannitol and i.v. hydration accompanied cisplatin administration. Prophylactic antiemetics included i.v. ondansetron (8 mg) prior to chemotherapy, oral hydration, and oral ondansetron 4 mg three times daily for 2 days. Treatment was administered on an outpatient basis for a maximum of six cycles. Re-treatment on day 22 required an ANC count ≥1.5 \times 10^{9}/l, a platelet count ≥100 \times 10^{9}/l, a creatinine clearance rate ≥50 ml min^{-1}, and resolution of all nonhaematological toxicities (except alopecia and fatigue) to baseline or less than grade 1. In case of a delay longer than 14 days, the patient was removed from the study. The doses of cisplatin and capecitabine were reduced following specific guidelines. Toxic events were recorded on a continuous basis, and followed until they were resolved to baseline or less than grade 1. Treatment compliance was evaluated using patient diaries and accounting unused drug. History and physical examination, complete blood cell counts, and serum biochemistry tests were performed at weekly intervals during treatment. Re-staging CT scans, chest radiographs, and upper respiratory tract examinations were performed every 3 cycles (9 weeks), or when clinically indicated.

Study end points

The primary end point of the study was tumour response. The criteria used to define response were standard RECIST criteria (Therasse et al., 2000). Secondary efficacy parameters were progression-free survival (PPS) and overall survival (OS). Progression-free survival and OS were defined as the time from diagnosis of recurrent or advanced disease to the last contact, or progression or death, respectively. Adverse events were classified and graded according to the National Cancer Institute Common Toxicity Criteria version 3.0. Patients were considered evaluable for response and toxicity once therapy was initiated.

Tissue microarray (TMA) design

A tissue arrayer device (Beecher Instrument, Silver Spring, MD, USA) was used to construct the TMAs. All slides were reviewed by expert pathologists (MRP and JLRP) to select areas containing tumour cells and to exclude those areas showing necrosis, inflammation, and keratinisation. To assess reproducibility, cylinders of 0.6 mm in diameter from two different areas were taken in each case. Tissue microarray blocks were constructed with the duplicated test sample and 12 controls. The latter specimens were used to ensure the quality, reproducibility, and homogenous staining of the slides, and consisted on archival reactive tonsil tissue. The samples were blindly scored, and when discordances between the duplicated specimens occurred an additional area was considered.

Immunohistochemistry

Sections (3-μm thick) were cut from the TMA and transferred to silanised glass slides. The sections were dried for 16 h at 56°C before being de-waxed in xylene and re-hydrated through a graded ethanol series and washed with phosphate-buffered saline. For antigen retrieval a treatment in a pressure cooker for 15 min in citrate buffer at 95°C was performed. Immunohistochemical staining was performed in an automated immunostainer, using the biotin–streptavidin-peroxidase procedure with diaminobenzidine as the chromogen. Haematoxylin was used for counterstaining. The following antigens were stained: TS (TS 106, Neomarkers, MS-471, 1:10 LSAB), thymidine phosphorylase (PD-ECGF Ab-1, Neomarkers, Pgf-44C, pre-diluted during 30 min), VEGF-R1/Flt-1 (h-225) (Polyclonal rabbit, Santa Cruz, 1/800), VEGFR2/FLK-1 (Monoclonal A-3, Santa Cruz Biotechnology, Inc., 1/50), VEGF-R1/Flt-1 (C-17) (Policlonal rabbit, Santa Cruz, 1/150). Reactivity for all antibodies was quantified by use of a visual grading system based on the intensity of cytoplasm staining (0–2) as follows: grade 0: no immunoreactivity, grade 1: if any specific staining, slightly stronger than background staining was detected, and grade 2: if clear immunoreactivity in more than half of the cancer cells were detected. The association of histologic factors with site of disease, type of disease, stage, and response to treatment was analysed; the impact of these factors on progression-free and overall survival was evaluated. Assessment included both no vs any expression, as well as no plus low vs high expression.

Microvessel counting

Blood vessels were visualised by staining endothelial cells for CD31 (Mouse monoclonal antibody J70a, Dako, Prosan, Belgium). One section per tumour was analysed. The entire section was analysed at ×20–40 magnification to identify the areas of most intense neovascularisation, that were identified as having the highest density of brown staining. Vascular hotspots were suitable for analysis provided they were adjacent to tumour cells. Whenever such a highly vascularised area was encountered at ×20–40 magnification, individual microvessels were counted and expressed as microvessels per field (MPF) at ×200 magnification. Neither vessel lumens nor the presence of red blood cells was used to define a microvessel, and no exclusion criteria based on size were used. The mean of the five highest counts per tumour was taken for further analyses. The predefined cutoff value for
Statistical analysis

The trial followed a two-stage Simon Minimax design (Thall et al., 1989), allowing early closure in case of treatment failure. The null hypothesis of a true response rate of 50% or lower was evaluated against the alternative hypothesis of a true response rate of 70% or higher (alpha error 0.05, beta error 0.20). In all, 13 responses were required in the first 23 patients to continue accrual, and 24 responses out of 37 patients were required to consider the regimen promising. Confidence intervals (CIs; 95%) were calculated with the exact method. Survival was estimated by the Kaplan–Meier product limit method (Kaplan and Meier, 1958). A Cox proportional hazards model was created to assess prognostic or predictive factors in a multivariate fashion. All tests were two-sided at the 0.05 level of significance. The SPSS (version 10.0, Chicago, USA) package was used for statistical analyses.

RESULTS

Patients

Between November 2001 and November 2002, 41 patients with locally advanced HNSCC were accrued into the study. All patients were assessable for toxicity and survival, and response could be evaluated in 40 patients. Demographic and clinical characteristics of the subjects are summarised in Table 1. A total of 18 patients presented a relapse from a previously diagnosed and treated HNSCC, that was locoregional in 14 cases, and both locoregional and distant in four patients (three lung, one skin). Four patients presented a second primary HNSCC, and 19 patients presented with unresectable disease at diagnosis; for the latter two groups, treatment was delivered as induction therapy. Nine patients had received prior chemotherapy; five (56%) had been treated with a combination of cisplatin, 5-FU and paclitaxel as neoadjuvant chemotherapy, and four (44%) had received cisplatin alone as concurrent chemoradiotherapy. In all, 15 patients had received radiotherapy. The median interval between initial diagnosis and relapse or second primary occurrence was 14 months (range 6–53 months).

Treatment administered

A total of 195 cycles of the study regimen were delivered (median five cycles; range 2–6 per patient): 20 patients (49%) received the six planned cycles, seven (17%) received five cycles, three (7%) received four cycles, six (15%) received three cycles, and five (12%) received two cycles. Most chemotherapy cycles were delivered at the planned doses (94%), and schedules (88%). Doses were reduced in 10 patients (due to seven, one and one episodes of haematologic toxicity, diarrhoea, and hand–foot syndrome (HFS), respectively). Treatment was delayed for a week in 15 patients (due to 13, 1, and 1 episodes of haematologic toxicity, mucositis, and HFS, respectively). Median treatment duration was 16 weeks (range 6–20). Median dose intensities were 25 mg m\(^{-2}\) per week of cisplatin (range 15.5–25), and 8.8 g m\(^{-2}\) per week of capecitabine (range 5.8–9.3). Median dose intensities achieved for cisplatin and capecitabine were 100 and 95% of the planned doses, respectively.

Response

In total, 15 responses were documented in the first stage (23 patients), and thus accrual continued. The overall response rate was 68% (28 out of 41 patients; 95% CI, 53–80%) (Table 2). There were 16 complete responses (39%), 12 partial responses (29%), five disease stabilisations (12%), and seven patients (17%) presented progressive disease as the best response to therapy. One patient (3%) was removed from the study due to cardiac toxicity before response assessment. Median time to response was 9 weeks (range, 8–10 weeks). Median duration of response was 5.6 months (range, 2.4–21 months; 95% CI, 4.2–6.9 months). All patients who ultimately achieved a clinical response were responding by cycle 3, but only 11 out of the 16 complete responses were achieved after three cycles of therapy. No differences were noted comparing response in untreated vs previously treated with cisplatin and/or
Clinical 2008
documented in nonradiated vs irradiated targets (85 vs 45%; \( P = 0.09 \)).

Toxicity
Haematologic and nonhaematologic toxicities are shown in Table 3. Grade 3–4 neutropenia was documented in five subjects, but no febrile neutropenic episodes were recorded. Median nadir ANC count was \( 2.2 \times 10^9/\text{l} \) (range, 0.34–11.2 \( \times 10^9/\text{l} \)). Thrombocytopenia was observed in six patients (15%), that was grade 3 in one subject (2%). Anaemia was documented in 29 patients (71%), and was grade 3 in three subjects (7%). Asthenia, anorexia, HFS, and constipation were the most frequent nonhaematologic events. Nine out of 41 patients (22%) suffered from grade 3 or 4 nonhaematologic adverse events, being the most frequent asthenia and anorexia (three grade 3 episodes each), and mucositis (two grade 3 events); the latter was unrelated to prior radiotherapy. Only one patient suffered from grade 3 HFS. One 47-year-old woman with a past history of smoking presented an episode of exercise-related angor pectoris on day 12 of the second cycle of therapy that responded to calcium-channel blockers, and was thought related to capcitabine administration; subsequently, she was removed from the study. Table 4 shows toxicity by treatment cycle.

Subsequent therapy and outcome
After completion of the study treatment, patients with disease control or unassessable were treated with radiotherapy (12), surgery plus radiotherapy (five), surgery (four), and 13 received no further therapy. Patients with progressive disease as the best response were treated with chemotherapy (four), chemotherapy and radiotherapy (two), and best supportive care (one).

In all, 33 patients have progressed; 27 patients recurred locoregionally, two patients presented distant metastases, and four patients presented both locoregional and distant disease. Median PFS was 6.4 months (95% CI, 5.7–7.3 months), and median survival after disease progression was 3 months (95% CI, 0.7–5.3 months). A total of 23 deaths have occurred, all of them related to tumour progression. Median overall survival was 12.6 months (95% CI, 10.0–15.2 months) (Figure 1). The multivariate model showed that achieving a complete response marginally predicted a better OS (\( P = 0.041 \)).

Comparison of patients with recurrent and primary unresectable disease
Results are summarised in Table 5. Response rates were similar between patients with recurrent disease and those with primary unresectable disease (61 vs 74%, respectively; \( P = 0.50 \)), although there was a trend towards a higher incidence of progressive disease in the recurrent group (9 vs 28%, \( P = 0.10 \)). Toxicity was equivalent between groups. PFS (6.5 vs 5.9 months, \( P = 0.40 \)) and OS (12.7 vs 12.9 months, \( P = 0.73 \)) showed no differences when comparing patients with recurrent and primary unresectable disease, respectively (Figure 2). However, the proportion of patients free of relapse at the moment of this analysis was marginally higher in patients with primary tumours (6 vs 30%, \( P = 0.046 \)).

Immunohistochemical evaluation
Tumour tissue from 31 patients was assessed. The levels of expression of TS, TP-cyt, TP-nuc, and VEGFR1 to 3 are shown in Table 6. The only factor that showed a significant association with any clinical or outcome parameters was TP-cyt (Table 7). High TP-cyt expression was more prevalent in patients with a laryngeal location than in those with neoplasms arising from other locations (83 vs 24%; \( P = 0.009 \)). In addition, a higher percentage of patients with a recurrence expressed high levels of TP-cyt when compared with those with primary disease (64 vs 12%; \( P = 0.007 \)). No

Table 3 Summary of haematologic and nonhaematologic toxicity

|                      | All grades | Grade 3–4 |
|----------------------|------------|-----------|
|                      | No. of patients | % | No. of patients | % |
| **Haematologic**     |             |   |             |   |
| Anaemia              | 29          | 71| 3           | 7 |
| Neutropenia          | 17          | 42| 5           | 12 |
| Thrombocytopenia     | 6           | 15| 1           | 2 |
| **Nonhaematologic**  |             |   |             |   |
| Asthenia             | 36          | 88| 3           | 7 |
| Anorexia             | 34          | 83| 3           | 7 |
| Hand–foot syndrome   | 27          | 66| 1           | 2 |
| Constipation         | 26          | 63| 0           | 0 |
| Nausea/vomiting      | 16          | 39| 0           | 0 |
| Alopecia             | 12          | 29| —           | — |
| Mucositis            | 11          | 27| 2           | 5 |
| Neuropathy           | 4           | 10| 0           | 0 |
| Diarrhoea            | 3           | 7 | 1           | 2 |
| Cardiotoxicity       | 1           | 2 | 1           | 2 |

Table 4 Toxicity by treatment cycle

| Grade | 1 (n = 41) | 2 (n = 40) | 3 (n = 36) | 4 (n = 30) | 5 (n = 27) | 6 (n = 20) |
|-------|------------|------------|------------|------------|------------|------------|
|       | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 |
| Anaemia| 6 | 1 | 0 | 0 | 1 | 1 | 0 | 7 | 2 | 1 | 0 | 12 | 3 | 0 | 0 | 7 | 6 | 1 | 0 | 9 | 2 | 1 | 0 |
| Neutropenia| 2 | 1 | 0 | 1 | 2 | 0 | 2 | 1 | 4 | 1 | 1 | 1 | 2 | 2 | 0 | 0 | 2 | 1 | 1 | 0 | 3 | 0 | 0 |
| Thrombocytopenia| 1 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 2 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 |
| Asthenia| 16 | 8 | 0 | 0 | 18 | 9 | 1 | 0 | 18 | 8 | 1 | 0 | 15 | 8 | 1 | 0 | 14 | 8 | 2 | 0 | 10 | 8 | 0 |
| Anorexia| 8 | 3 | 0 | 0 | 11 | 8 | 0 | 0 | 16 | 6 | 1 | 0 | 11 | 7 | 1 | 0 | 14 | 8 | 2 | 0 | 11 | 6 | 0 |
| Hand–foot syndrome| 0 | 0 | 0 | 0 | 1 | 0 | 0 | 8 | 2 | 0 | 0 | 16 | 3 | 1 | 0 | 8 | 10 | 1 | 0 | 6 | 11 | 0 |
| Constipation| 11 | 2 | 0 | 0 | 12 | 4 | 0 | 0 | 9 | 3 | 0 | 0 | 12 | 1 | 0 | 0 | 11 | 2 | 0 | 0 | 6 | 3 | 0 |
| Nausea/vomiting| 6 | 1 | 0 | 0 | 5 | 0 | 0 | 0 | 4 | 0 | 0 | 0 | 2 | 3 | 0 | 0 | 2 | 0 | 0 | 0 | 1 | 1 | 0 |
| Alopecia| 0 | 0 | — | — | 2 | 0 | — | 9 | 0 | — | — | 8 | 0 | — | — | 8 | 1 | — | — | 7 | 0 | — |
| Mucositis| 3 | 1 | 2 | 0 | 2 | 2 | 0 | 0 | 2 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 2 | 0 | 0 |
| Neuropathy| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Diarrhoea| 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cardiotoxicity| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
significant correlation was found between TP-cyt and TP-nuc (Pearson, \( r = 0.23; P = 0.22 \)). No other differences were found. MVD count was higher in patients with a recurrence than in those with primary disease (31 ± 7 vs 23 ± 6 MPF; \( P = 0.012 \)). There were no differences in MVD when stratifying patients according to clinical characteristics, or the expression of other histologic factors. No significant correlation was found between MVD and TP-cyt (Pearson, \( r = 0.15; P = 0.47 \)), or TP-nuc (Pearson, \( r = -0.15; P = 0.47 \)). Patients with an MVD above the median (23 MPF) showed a trend towards a longer OS compared to those with an MVD below the median (12.9 vs 10.1 months; \( P = 0.074 \)).

**DISCUSSION**

The combination of cisplatin and capecitabine at the doses evaluated showed a significant level of activity, and a good tolerability. The median number of cycles administered and the dose intensity achieved highlight the feasibility of this regimen. Although it was not the purpose of this trial, and with due caution considering the limited sample size, it is not adventurous to affirm that this regimen shows at least a similar level of activity as that of cisplatin and infusional 5FU. The relative heterogeneity of this cohort of patients permitted to establish a number of thought-provoking comparisons. No difference in terms of efficacy was observed between patients with a relapse and those with primary disease, nor was any dissimilarity evidenced between cisplatin and/or 5FU-treated and previously untreated subjects. Also, the response rate according with prior target irradiation was nonsignificantly higher in nonradiated patients. However, considering the low number of patients analysed, these observations have to be interpreted with caution.

Interestingly, all patients who ultimately responded had significant tumour shrinkage after three cycles, an observation that emphasises the activity of the regimen; notwithstanding, five out of 16 complete responders needed four or more cycles to achieve a maximal effect. This observation may be relevant in considering the low number of patients analysed, these observations have to be interpreted with caution.

All patients responding by cycle three will benefit from further therapy. This observation may be relevant in considering the low number of patients analysed, these observations have to be interpreted with caution.

Considering the limited sample size, it is not adventurous to affirm that this regimen shows at least a similar level of activity as that of cisplatin and infusional 5FU. The relative heterogeneity of this cohort of patients permitted to establish a number of thought-provoking comparisons. No difference in terms of efficacy was observed between patients with a relapse and those with primary disease, nor was any dissimilarity evidenced between cisplatin and/or 5FU-treated and previously untreated subjects. Also, the response rate according with prior target irradiation was nonsignificantly higher in nonradiated patients. However, considering the low number of patients analysed, these observations have to be interpreted with caution.

Interestingly, all patients who ultimately responded had significant tumour shrinkage after three cycles, an observation that emphasises the activity of the regimen; notwithstanding, five out of 16 complete responders needed four or more cycles to achieve a maximal effect. This observation may be relevant in considering the low number of patients analysed, these observations have to be interpreted with caution.
Toxicity was moderate and manageable; anaemia was the main haematological toxicity and was predominantly grade 1. Neutropenia was documented in five patients but none of them developed related infectious complications. This profile of haematological toxicity is lower than that consistently reported with cisplatin–5FU (Forastiere et al., 2003). The most common nonhaematologic toxicities were asthenia, anorexia, HFS, and constipation. Of note, a patient developed angor pectoris while receiving capecitabine, an event that highlights the pharmacologic similarities of this drug to infusional 5FU. The toxicity profile appears to be milder to that reported by Pivot et al. (2005), even considering that the average number of cycles per patient is higher in the current study (2.5 vs 4.8 cycles per patient (median not reported)). Also efficacy in the present study was higher. Differences in patient population may explain these findings; in fact, all patients enrolled in that phase I study had been previously treated with chemotherapy, as opposed to only 22% of patients in this study. However, the higher dose of cisplatin used (17 out of 21 patients received 100 mg m⁻²) may be partially responsible for the increased incidence of adverse events; in view of the efficacy of the current schedule and the relative equivalency of lower vs higher doses of cisplatin in advanced HNSCC patients (Veronesi et al., 1985), 75 mg m⁻² seems to be a reasonable cisplatin dose to administer in combination with capecitabine.

As long as it maintains equivalent efficacy, patients generally prefer oral administration of chemotherapy to intravenous infusions (Liu et al., 1997), but oral therapy may theoretically be difficult in patients with HNSCC who frequently have swallowing dysfunction related either to their tumour or its treatment. However, this was not the case in the present report, a fact underlined by the high compliance with oral chemotherapy documented (98%).

Tumour angiogenesis manifested as increased MVD counts or VEGF expression has been shown to adversely impact outcome and treatment results in HNSCC patients in several series (O-Charnoenrat et al., 2001; Mineta et al., 2002). After analysing 94 patients with unresectable HNSCC treated with chemoradiation, Koukourakis et al. (2000) concluded that TP-nuc expression was associated with angiogenesis as assessed by MVD, with resistance to radiotherapy and cytotoxic therapy, and with poorer survival in squamous cell head and neck cancer. TP is a pertinent factor to be assessed in this clinical context given its unique duality: it is both the activator of one of the drugs administered (and thus with potential predictive capability), and a potent proangiogenic factor. Recently, Brown et al. (2000) showed that TP induces oxidative stress to cancer cells, and promotes secretion of angiogenic factors such as VEGF. In the present report, TP-cyt expression was found to be significantly more prevalent in patients with laryngeal cancer compared with other locations, and in relapsed patients. The significance of the former finding remains obscure, whereas the latter observation may be related to the aggressiveness of the disease. The second potential predictive factor of response assessed was TS. A previous study shows that low intratumoral expression of TS was a strong predictor of response to 5FU-based therapy of disseminated colorectal cancers, and strongly correlated with a longer survival (Leichman et al., 1997). However, no relationship was found between TP (either nuclear or cytoplasmic) or TS and activity in the current series. The levels of the VEGFR are correlated with a poorer grade of tumour differentiation and prognosis in pancreatic cancer (Buchler et al., 2002). The fact that in the current series the majority of patients expressed high levels of VEGFR2 but none expressed high levels of VEGFR1, together with the lack of correlation with MVD, suggests that the sensitivity and/or specificity of the technique may not be optimal. However, and this also applies to TP/TS expression, the interpretation of these results is constrained by the relatively low number of patients analysed.

MVD count was significantly higher in relapsed patients than in those with primary disease, and it could be hypothesised that a higher MVD in recurrences indicates a more aggressive behaviour, but the present study is underpowered to address this issue. The fact that both MVD and TP-nuc were concomitantly elevated in relapsed patients may indirectly confirm the association between these two factors in prior reports (Koukourakis et al., 2000). It is also somehow paradoxical that patients with an MVD above the median showed a trend towards a better outcome; however, the multivariate analysis showed no relationship between MVD (either as a continuous value of grouping according to the median) and OS. It is increasingly evident that univariate results from studies involving analysis of biologic factors have to be cautiously interpreted, considering the numerous stratifications and comparisons performed.

In summary, this cisplatin–capecitabine schedule in recurrent or unresectable HNSCC is feasible and effective in terms of tumour response, and comparative, multicentre trials with cisplatin–5FU seem warranted.

REFERENCES

Brown NS, Jones A, Fujiyama C, Harris AL, Bicknell R (2000) Thymidine phosphorylase induces carcinoma cell oxidative stress and promotes secretion of angiogenic factors. Cancer Res 60: 6298 – 6302

Buchler P, Reber HA, Buchler MW, Friess H, Hines OJ (2002) VEGF-RII influences the prognosis of pancreatic cancer. Ann Surg 236: 738 – 749; discussion 749

Campbell JB, Dorman EB, McCormick M, Miles J, Morton RP, Rugman F, Stell PM, Stoney PJ, Vaughan ED, Wilson JA (1987) A randomized phase I trial of cisplatin, methotrexate, cisplatin + methotrexate, and cisplatin + 5-fluoro-uracil in end-stage head and neck cancer. Acta Otolaryngol 103: 513 – 528

Clavel M, Vermorken JB, Cappelletti P, Cappelaere P, De Mulder PH, Schornagel JH, Tueni EA, Verweij J, Wildiers J, Clerico M (1994) Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CAβO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. A phase III study of the EORTC Head and Neck Cancer Cooperative Group. Ann Oncol 5: 521 – 526

Dimery IW, Hong WK (1993) Overview of combined modality therapies for head and neck cancer. J Natl Cancer Inst 85: 95 – 111

Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, Glisson B, Trotti A, Ridge JA, Chao C, Peters G, Lee DJ, Leaf A, Ensign J, Cooper J (2003) Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 349: 2091 – 2098

Forastiere AA, Mitch B, Schuller DE, Ensign JF, Hutchins LF, Trizio P, Kish JA, McClure S, VonFeldt E, Williamson SK (1992) Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol 10: 1245 – 1251

Ishikawa T, Sekiguchi F, Fukase Y, Sawada N, Ishitsuka H (1998a) Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts. Cancer Res 58: 683 – 690

Ishikawa T, Uoto M, Sawada N, Nishida M, Fukase Y, Sekiguchi F, Ishitsuka H (1998b) Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts. Biochem Pharmacol 55: 1091 – 1097

Jacobs C (1994) Head and neck cancer in 1994: a change in the standard of care. J Natl Cancer Inst 86: 250 – 252

Jacobs C, Lyman G, Velez-Garcia E, Sridhar KS, Knight W, Hochster H, Goodnough LT, Mortimer JE, Einhorn LH, Schacter L et al. (1992) A phase III randomized study comparing cisplatin and fluorouracil as...
single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 16: 257 – 263
Kaplan E, Meier P (1958) Nonparametric estimation for incomplete observations. J Am Stat Assoc 53: 447
Kono A, Hara Y, Sugata S, Karube Y, Matsushima Y, Ishitsuka H (1983) Activation of 5'-deoxy-5-fluorouridine by thymidine phosphorylase in human tumors. Chem Pharm Bull (Tokyo) 31: 175 – 178
Koukourakis MI, Giatromanolaki A, Fountzilas G, Sivridis E, Gatter KC, Harris AL (2000) Angiogenesis, thymidine phosphorylase, and resistance of squamous cell head and neck cancer to cytotoxic and radiation therapy. Clin Cancer Res 6: 381 – 389
Leichman CG, Lenz HJ, Leichman L, Danenberg K, Baranda J, Groschen S, Boswell W, Metzger R, Tan M, Danenberg PV (1997) Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol 15: 3223 – 3229
Liggett Jr W, Forastiere AA (1995) Chemotherapy advances in head and neck oncology. Semin Surg Oncol 11: 265 – 271
Liu G, Franssen E, Fitch MI, Warner E (1997) Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 15: 110 – 115
Mineta H, Miura K, Ogino T, Takebayashi S, Misawa K, Ueda Y (2002) Vascular endothelial growth factor (VEGF) expression correlates with p53 and ki-67 expressions in tongue squamous cell carcinoma. Anticancer Res 22: 1039 – 1044
Okamoto E, Osaki M, Kase S, Adachi H, Kaibara N, Ito H (2001) Thymidine phosphorylase expression causes both the increase of intratumoral microvessels and decrease of apoptosis in human esophageal carcinomas. Pathol Int 51: 158 – 164
O-Charoenrat P, Rhys-Evans P, Eccles S (2001) Expression of vascular endothelial growth factor family members in head and neck squamous cell carcinoma correlates with lymph node metastasis. Cancer 92: 556 – 568
Pivot X, Chamorey E, Guardiola E, Magne N, Thys A, Otto J, Giroux B, Mouri Z, Schneider M, Milano G (2003) Phase I and pharmacokinetic study of the association of capecitabine–cisplatin in head and neck cancer patients. Ann Oncol 14: 1578 – 1586
Takebayashi Y, Yamada K, Miyadera K, Sumizawa T, Furukawa T, Kinoshita F, Aoki D, Okumura H, Yamada Y, Akiyama S, Aikou T (1996) The activity and expression of thymidine phosphorylase in human solid tumours. Eur J Cancer 32A: 1227 – 1232
Thall PF, Simon R, Ellenberg SS (1989) A two-stage design for choosing among several experimental treatments and a control in clinical trials. Biometrics 45: 537 – 547
Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein LV, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205 – 216
Veronesi A, Zagonel V, Tirelli U, Galligioni E, Tumolo S, Barzan L, Lorenzini M, Comoretto R, Grigoletto E (1985) High-dose versus low-dose cisplatin in advanced head and neck squamous carcinoma: a randomized study. J Clin Oncol 3: 1105 – 1108
Zimmerman M, Seidenberg J (1964) Deoxyribosyl transfer. I. Thymidine phosphorylase and nucleoside deoxyribosyltransferase in normal and malignant tissues. J Biol Chem 239: 2618 – 2621